Based on these encouraging results, Torres-Benito et al. [89] developed an ASO-based therapy to target Ncald in mouse spinal cord and used it in combination with low-dose SMN splice switching ASOs to design an efficient combinatorial therapy in SMA mice [89]. Here, SMN2 is linked to proximal spinal muscular atrophy.